Moderna submits 'rolling' application as part of process to obtain full FDA approval for its COVID-19 shot

Dow Jones2021-06-01

MW Moderna submits 'rolling' application as part of process to obtain full FDA approval for its COVID-19 shot

Shares of Moderna Inc. $(MRNA)$ gained 0.1% in premarket on Tuesday after the company said it is formally seeking full approval from the Food and Drug Administration for its COVID-19 vaccine. Moderna said it has initiated a rolling submission to the FDA; the company's shot was the second to receive emergency use authorization in the U.S., back in December. Pfizer Inc. $(PFE)$, which also developed an mRNA-based COVID-19 vaccine, with BioNTech SE (BNTX), was the first to receive authorization. It has also submitted a rolling submission to U.S. regulators for approval. Moderna's stock is up 77.1% for the year, while the broader S&P 500 has gained 11.9%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

$(END)$ Dow Jones Newswires

June 01, 2021 07:59 ET (11:59 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

valerie
2021-06-01
valerie
[Smile]

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2140462117?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-01 19:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2140462117","market":"us","top_or_hot":-1,"title":"Moderna submits 'rolling' application as part of process to obtain full FDA approval for its COVID-19 shot","media":"Dow Jones","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Moderna submits 'rolling' application as part of process to obtain full FDA approval for its COVID-19 shot\n</p>\n<p>\n  Shares of Moderna Inc. <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> gained 0.1% in premarket on Tuesday after the company said it is formally seeking full approval from the Food and Drug Administration for its COVID-19 vaccine. Moderna said it has initiated a rolling submission to the FDA; the company's shot was the second to receive emergency use authorization in the U.S., back in December. Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a>, which also developed an mRNA-based COVID-19 vaccine, with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX), was the first to receive authorization. It has also submitted a rolling submission to U.S. regulators for approval.  Moderna's stock is up 77.1% for the year, while the broader S&amp;P 500  has gained 11.9%. \n</p>\n<p>\n  -Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  June 01, 2021 07:59 ET (11:59 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna submits 'rolling' application as part of process to obtain full FDA approval for its COVID-19 shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna submits 'rolling' application as part of process to obtain full FDA approval for its COVID-19 shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 19:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>MW Moderna submits 'rolling' application as part of process to obtain full FDA approval for its COVID-19 shot\n\n\n  Shares of Moderna Inc. $(MRNA)$ gained 0.1% in premarket on Tuesday after the company ...</p>\n\n<a href=\"http://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2140462117","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2140462117","pubTimestamp":1622548740,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"MW Moderna submits 'rolling' application as part of process to obtain full FDA approval for its COVI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"translate_title":"Moderna提交“滚动”申请，作为获得FDA全面批准其新冠肺炎疫苗程序的一部分","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":0.9,"MRNA":0.9,"PFE":0.9},"content_text":"MW Moderna submits 'rolling' application as part of process to obtain full FDA approval for its COVID-19 shot\n\n\n  Shares of Moderna Inc. $(MRNA)$ gained 0.1% in premarket on Tuesday after the company said it is formally seeking full approval from the Food and Drug Administration for its COVID-19 vaccine. Moderna said it has initiated a rolling submission to the FDA; the company's shot was the second to receive emergency use authorization in the U.S., back in December. Pfizer Inc. $(PFE)$, which also developed an mRNA-based COVID-19 vaccine, with BioNTech SE (BNTX), was the first to receive authorization. It has also submitted a rolling submission to U.S. regulators for approval.  Moderna's stock is up 77.1% for the year, while the broader S&P 500  has gained 11.9%. \n\n\n  -Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  June 01, 2021 07:59 ET (11:59 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":119287539,"gmtCreate":1622549749021,"gmtModify":1704186091700,"author":{"id":"3562023366191758","authorId":"3562023366191758","name":"valerie","avatar":"https://static.tigerbbs.com/684f10cddc1d49552416b0d47347efd7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3562023366191758","authorIdStr":"3562023366191758"},"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119287539","repostId":2140462117,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2140462117"}